{"id":"W2889698651","doi":"10.1200/jco.2018.36.15_suppl.5003","title":"Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Olaparib; Internal medicine; Placebo; Clinical endpoint; Prostate cancer; Abiraterone; Progression-free survival; Oncology; Urology; Randomized controlled trial; Gastroenterology; Cancer; Chemotherapy; Pathology; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000906872,0.001268369,0.001726466,0.0003618649,0.0003115964,0.001070333,0.0006126597,0.001076205,0.006545643],"category_scores_gemma":[0.0009520956,0.0005952519,0.001137089,0.0005433681,0.0006643919,0.0006715046,0.0003414439,0.002106712,0.0009938726],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005085427,"about_ca_system_score_gemma":0.000818093,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007618447,"about_ca_topic_score_gemma":0.001962648,"domain_scores_codex":[0.9997084,0.0001541462,0.00002082556,0.00005134668,0.00002429226,0.00004097015],"domain_scores_gemma":[0.9995463,0.00009805227,0.000121957,0.00002863038,0.00002499342,0.0001798969],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9643995,0.007856634,0.0009864492,0.0007744131,0.0007078261,0.00007535609,0.00006181197,0.0003643286,0.003800414,0.0000845249,0.0007949324,0.02009378],"study_design_scores_gemma":[0.9295917,0.06725896,0.001513027,0.00002920872,0.0003326432,0.00007125515,0.0000200574,0.0002229089,0.0002427855,0.00008398679,0.0006247586,0.000008754112],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9843926,0.006531167,0.0005239316,0.0006486286,0.0003357652,0.004013524,0.001403359,0.0001190016,0.002031993],"genre_scores_gemma":[0.985023,0.004837313,0.001035366,0.0009120991,0.0004104516,0.003584336,0.001356518,0.00001875562,0.002822108],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006545643,"threshold_uncertainty_score":0.02189732,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0999205760092294,"score_gpt":0.4754539768126198,"score_spread":0.3755334008033904,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}